509 related articles for article (PubMed ID: 25829373)
1. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.
Rosso-Fernández C; Sojo-Dorado J; Barriga A; Lavín-Alconero L; Palacios Z; López-Hernández I; Merino V; Camean M; Pascual A; Rodríguez-Baño J;
BMJ Open; 2015 Mar; 5(3):e007363. PubMed ID: 25829373
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of antibiotic treatments for urinary tract infections in the elderly, especially regarding the effect on extended spectrum β-lactamase producing (ESBL-) Escherichia coli: A comparison between meropenem and alternatives].
Yamamoto A; Yamasaki K
Nihon Ronen Igakkai Zasshi; 2015; 52(2):153-61. PubMed ID: 25994987
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
[TBL] [Abstract][Full Text] [Related]
4. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection.
Senol S; Tasbakan M; Pullukcu H; Sipahi OR; Sipahi H; Yamazhan T; Arda B; Ulusoy S
J Chemother; 2010 Oct; 22(5):355-7. PubMed ID: 21123160
[TBL] [Abstract][Full Text] [Related]
5. Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase Escherichia coli urinary tract infection treatment.
Deemer K; Grey J; Fronczek C; Marr K
Am J Health Syst Pharm; 2020 Nov; 77(Supplement_4):S105-S110. PubMed ID: 32840305
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.
Zykov IN; Samuelsen Ø; Jakobsen L; Småbrekke L; Andersson DI; Sundsfjord A; Frimodt-Møller N
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581117
[TBL] [Abstract][Full Text] [Related]
7. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
Aris P; Boroumand MA; Rahbar M; Douraghi M
Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
[TBL] [Abstract][Full Text] [Related]
8. Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST).
Ten Doesschate T; van Mens SP; van Nieuwkoop C; Geerlings SE; Hoepelman AIM; Bonten MJM
BMC Infect Dis; 2018 Dec; 18(1):626. PubMed ID: 30518334
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial.
Sojo-Dorado J; López-Hernández I; Rosso-Fernandez C; Morales IM; Palacios-Baena ZR; Hernández-Torres A; Merino de Lucas E; Escolà-Vergé L; Bereciartua E; García-Vázquez E; Pintado V; Boix-Palop L; Natera-Kindelán C; Sorlí L; Borrell N; Giner-Oncina L; Amador-Prous C; Shaw E; Jover-Saenz A; Molina J; Martínez-Alvarez RM; Dueñas CJ; Calvo-Montes J; Silva JT; Cárdenes MA; Lecuona M; Pomar V; Valiente de Santis L; Yagüe-Guirao G; Lobo-Acosta MA; Merino-Bohórquez V; Pascual A; Rodríguez-Baño J;
JAMA Netw Open; 2022 Jan; 5(1):e2137277. PubMed ID: 35024838
[TBL] [Abstract][Full Text] [Related]
10. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.
Dickstein Y; Leibovici L; Yahav D; Eliakim-Raz N; Daikos GL; Skiada A; Antoniadou A; Carmeli Y; Nutman A; Levi I; Adler A; Durante-Mangoni E; Andini R; Cavezza G; Mouton JW; Wijma RA; Theuretzbacher U; Friberg LE; Kristoffersson AN; Zusman O; Koppel F; Dishon Benattar Y; Altunin S; Paul M;
BMJ Open; 2016 Apr; 6(4):e009956. PubMed ID: 27098822
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility and mechanisms of fosfomycin resistance in extended-spectrum β-lactamase-producing Escherichia coli strains from urinary tract infections in Wenzhou, China.
Bi W; Li B; Song J; Hong Y; Zhang X; Liu H; Lu H; Zhou T; Cao J
Int J Antimicrob Agents; 2017 Jul; 50(1):29-34. PubMed ID: 28456703
[TBL] [Abstract][Full Text] [Related]
12. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.
Harris PN; Peleg AY; Iredell J; Ingram PR; Miyakis S; Stewardson AJ; Rogers BA; McBryde ES; Roberts JA; Lipman J; Athan E; Paul SK; Baker P; Harris-Brown T; Paterson DL
Trials; 2015 Jan; 16():24. PubMed ID: 25623485
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli.
Abe Y; Inan-Erdogan I; Fukuchi K; Wakabayashi H; Ogawa Y; Hibino S; Sakurai S; Matsuhashi K; Watanabe Y; Hashimoto K; Ugajin K; Itabashi K
J Infect Chemother; 2017 Aug; 23(8):517-522. PubMed ID: 28528936
[TBL] [Abstract][Full Text] [Related]
14. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
[TBL] [Abstract][Full Text] [Related]
15. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Wilson DT; May DB
Am J Ther; 2013; 20(6):685-90. PubMed ID: 21768870
[TBL] [Abstract][Full Text] [Related]
16. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli.
Oteo J; Bautista V; Lara N; Cuevas O; Arroyo M; Fernández S; Lázaro E; de Abajo FJ; Campos J;
J Antimicrob Chemother; 2010 Nov; 65(11):2459-63. PubMed ID: 20851815
[TBL] [Abstract][Full Text] [Related]
17. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
[TBL] [Abstract][Full Text] [Related]
18. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
[TBL] [Abstract][Full Text] [Related]
19. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study.
Matthews PC; Barrett LK; Warren S; Stoesser N; Snelling M; Scarborough M; Jones N
BMC Infect Dis; 2016 Oct; 16(1):556. PubMed ID: 27729016
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
